Ayesha Alvero
Professor, Research
Ayesha Alvero
Academic Rank
Professor, Department of Obstetrics and Gynecology
Professor, Department of Oncology
Biography
Dr. Alvero is a Cancer Biologist specializing in ovarian cancer research. Her groundbreaking work has elucidated specific molecular mechanisms that enable cancer stem cells to evade apoptosis and develop chemoresistance. She has identified targetable alternative cell death pathways that can bypass apoptosis in chemoresistant cancer cells, leading to robust proof-of-concept studies supporting clinical trials for several promising therapies, including Phenoxodiol, a chemosensitizer; NV-128/ME-344, an isoflavone-derived mitochondrial inhibitor; and Cantrixil, a potent and selective cytotoxic super-benzopyran.
Prior to joining the C.S. Mott Center, Dr. Alvero received her research training and served as faculty in the Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine. Her current research focuses on identifying targetable molecular mechanisms to prevent ovarian cancer recurrence, with an emphasis on resistance to immunotherapies and the role of the tumor microenvironment in sustaining recurrent disease. Her most recent publication highlights the potential of dendritic cell-based vaccination and oncoimmuno-modulatory virus-like vesicles in preventing recurrent ovarian cancer.
Education
M. Sc. Molecular and Cellular Biology, University of New Haven, West Haven, CT, USA
M.D. University of the East, Manila, Philippines
B.S. Biology, De La Salle University, Manila, Philippines
Post Graduate Training
Post-doctoral Fellowship, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University, New Haven, CT, USA
Post-doctoral Fellowship, Department of Therapeutic Radiology, Yale University, New Haven, CT, USA
Links of Interest
News
https://www.onclive.com/view/dr-alvero-on-antitumor-immunological-memory-in-ovarian-cancer-models
Publications
Peer-reviewed original articles from past 2 years
- Fox A, Leonard G, Adzibolosu N, Wong T, Tedja R, Sharma S, Gogoi R, Morris R, Mor G, Fehl C, Alvero AB. Adipose microenvironment promotes hypersialylation of ovarian cancer cells. Front Oncol, 2024, July 222. doi: 10.3389/fonc.2024.1432333.
- Chehade H, Gogoi R, Adzibolosu N, Galoforo S, Fehmi R, Kheil M, Fox A, Kim S, Rattan R, Hou Z, Morris R, Matherly L, Mor G, Alvero AB. BRCA status dictates Wnt responsiveness in epithelial ovarian cancer. Cancer Res Commun, 2024, Aug 1; 4(8):2075-2088. doi: 10.1158/2767-9764.CRC-24-0111.
- Wong T, Tedja R, Chehade H, Morris R, Alvero AB, Mor G. An ex vivo model of ovarian cancer peritoneal metastasis using human omentum. J Vis Exp. 2024 Jan 26; (203). doi: 10.3791/66031.
- Alvero AB, Fox A, Madina B, Krady M, Gogoi R, Chehade H, Nakaar V, Almassian B, Yarovinsky T, Rutherford T, Mor G. Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory. Cancer Immunol Res, 2023, Dec 11. doi: 10.1158/2326-6066.CIR-23-0127.
- Zhang Y, Tedja R, Millman M, Wong T, Fox A, Chehade H, Gershater M, Adzibolosu N*, Gogoi R, Anderson M, Rutherford T, Zhang Z, Chopp M, Mor G, Alvero AB. Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells. J Ovarian Res, 2023; 16 (1): 233.
- Gogoi R, Galoforo S, Fox A, Morris C, Ramos H, Gogoi V, Chehade H, Adzibolosu N, Shi C, Zhang J, Tedja R, Morris R, Alvero AB, Mor G. A Novel Role of Connective Tissue Growth Factor in the Regulation of the Epithelial Phenotype. Cancers, 2023; 15(19): 4834.
- Tedja R, Alvero AB, Fox A, Cardenas C, Pitruzzello M, Chehade H, Bawa T, Adzibolosu N, Gogoi R, Mor G. Generation of Stable Epithelial–Mesenchymal Hybrid Cancer Cells with Tumorigenic Potential. Cancers, 2023; 15(3):684.
- Adzibolosu N, Alvero AB, Ali-Fehmi R, Gogoi R, Corey L, Tedja R, Chehade H, Gogoi V, Morris R, Anderson M, Vitko J, Craig DB, Draghici S, Rutherford T, Mor G. Immunological modification following chemotherapy are associated with delayed recurrence in ovarian cancer. Front Immunol. 2023; 14:1204148.
- You Y, Grasso E, Alvero A, Condon J, Dimova T, Hu A, Ding J, Alexandrova M, Manchorova D, Dimitrova V, Liao A, Mor G. Twist1-IRF9 interaction is necessary for IFN-stimulated gene anti-Zika viral infection. J Immunol: 2023; May 5:ji2300081.
- H Chehade, N Adzibolosu, S Jayee, A Singh, R Tedja, R Gogoi, S Aras, L Grossman, G Mor , A Alvero. MNRR1 is a driver of ovarian cancer progression. Translational Oncology. 2023 Mar;29:101623.